Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | LPL | P06858 | 8/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13412137 | 0.87 | FFAR1 (0.59) | FFAR1LPLLIPGDGAT1AAK1 | |
| SCHEMBL14746347 | 0.87 | FFAR1 (0.56) | FFAR1LPLLIPGDGAT1AAK1 | |
| SCHEMBL30124853 | 0.84 | FFAR1 (0.53) | FFAR1LPLLIPGDGAT1AAK1 | |
| SCHEMBL2588010 | 0.84 | FFAR1 (0.59) | FFAR1LPLLIPGDGAT1AAK1 | |
| SCHEMBL24686402 | 0.84 | FFAR1 (0.52) | FFAR1LPLLIPGDGAT1AAK1 | |
| SCHEMBL23022205 | 0.83 | FFAR1 (0.52) | FFAR1LPLLIPGDGAT1AAK1 | |
| SCHEMBL34468062 | 0.83 | FFAR1 (0.57) | FFAR1LPLLIPGDGAT1AAK1 | |
| SCHEMBL19861553 | 0.81 | FFAR1 (0.56) | FFAR1LPLLIPGDGAT1AAK1 | |
| SCHEMBL29584057 | 0.80 | FFAR1 (0.52) | FFAR1LPLLIPGDGAT1F11 | |
| SCHEMBL19524038 | 0.80 | FFAR1 (0.61) | FFAR1LPLLIPGDGAT1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| WO-2021188695-A1 | FORMULATIONS OF A FARNESOID X RECEPTOR AGONIST | METACRINE, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20160194290-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194290-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | FFAR1 4389/4885LPL 4484/4885LIPG 4258/4885 |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | FFAR1 4389/4885LPL 4484/4885LIPG 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.